RxDoctor Payments Data

Margaret Parsons, MD

Procedural Dermatology · Sacramento, CANPI 1609952860

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 32.3% of the total. That places this record below the midpoint for procedural dermatology clinicians in CA, where the typical reported total is $2,566.

$2,687in general payments, 2019–2025

Across 196 payments — averaging $13.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$868
  • Lilly USA, LLC$299
  • Sanofi$229
  • Novartis$227
  • Regeneron Healthcare Solutions, Inc.$205
  • Incyte Corporation$169
  • plus $689 from 15 others

What the payments were for

  • Food & beverage$2,64398%
  • Education$442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,687 in reported general payments places this provider in the 50th percentile of 108 procedural dermatology providers in California.

See all procedural dermatology providers in California

Medicare billing

Part B allowed, 2024
$402,762
Medicare patients
1,191
Services billed
6,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab16$215,282
OtezlaApremilast17$90,347
Dupixent PenDupilumab13$49,857
Fluorouracil99$6,507
Calcipotriene24$5,132
Ivermectin24$5,065
Metronidazole79$3,853
Betamethasone Dipropionate68$2,446
Pimecrolimus15$2,352
Azelaic Acid16$1,972
Clobetasol Propionate38$1,487
Ketoconazole70$1,294
Triamcinolone Acetonide172$1,141
Hydroxychloroquine Sulfate12$1,020
Imiquimod31$963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$868$215,28216 claims
AmgenOtezla$81$90,34717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 108 procedural dermatology providers in California.

Other procedural dermatology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →